%0 Journal Article
%T App-based assessment of patient-reported outcomes in the Molecular Tumor Board in the Center for Personalized Medicine-(TRACE).
%A Dörner L
%A Grosse L
%A Stange F
%A Hille H
%A Kurz S
%A Becker H
%A Volkmer S
%A Hippler M
%A Rieger D
%A Bombach P
%A Rieger J
%A Weinert L
%A Svensson L
%A Anders C
%A Cekin S
%A Paulsen F
%A Öner Ö
%A Ruhm K
%A Malek HS
%A Möller Y
%A Tatagiba M
%A Wallwiener M
%A Eckert N
%A Escher P
%A Pfeifer N
%A Forschner A
%A Bauer A
%A Zips D
%A Bitzer M
%A Malek N
%A Gani C
%A Tabatabai G
%A Renovanz M
%J Neurooncol Pract
%V 11
%N 3
%D 2024 Jun
%M 38737615
暂无%R 10.1093/nop/npae002
%X <B>UNASSIGNED: </B>Biomarker-based therapies are increasingly used in cancer patients outside clinical trials. Systematic assessment of patient-reported outcomes (PRO) is warranted to take patients' perspectives during biomarker-based therapies into consideration. We assessed the feasibility of an electronic PRO assessment via a smartphone application.<BR><B>UNASSIGNED: </B>An interdisciplinary expert panel developed a smartphone application based on symptom burden and health-related quality of life (HRQoL) metrics reported in a retrospective analysis of 292 neuro-oncological patients. The app included validated assessments of health-related quality of life (HRQoL), the burden of symptoms, and psychological stress. Feasibility and usability were tested in a pilot study. Semi-structured interviews with patients and health care professionals (HCP) were conducted, transcribed, and analyzed according to Mayring´s qualitative content analysis. Furthermore, we assessed compliance and descriptive data of ePROs.<BR><B>UNASSIGNED: </B>A total of 14 patients have been enrolled, (9 female, 5 male). A total of 4 HCPs, 9 patients, and 1 caregiver were interviewed regarding usability/feasibility. The main advantages were the possibility to complete questionnaires at home and comfortable implementation in daily life. Compliance was high, for example, 82% of the weekly distributed NCCN distress thermometer questionnaires were answered on time, however, with interindividual variability. We observed a median distress score of 5 (range 0-10, 197 results, n = 12, weekly assessed) and a median Global health score of 58.3 according to the EORTC QLQ-C30 instrument (range 16.7-100, 77 results, n = 12, monthly assessed).<BR><B>UNASSIGNED: </B>This pilot study proved the feasibility and acceptance of the app. We will therefore expand its application during biomarker-guided therapies to enable systematic PRO assessments.